reviewThe Lancet OncologyJan 1, 2019GREEN OA

Exploring and comparing adverse events between PARP inhibitors

CJChristopher J. LafargueGZGraziela Zibetti Dal MolinAKAnil K. SoodRLRobert L. Coleman

The University of Texas MD Anderson Cancer Center

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

471
total citations
FWCI
20.27
Percentile
100%
References
82
Citations per year

Authors

4

Topics & keywords

Topics
Keywords
  • Adverse effect
  • Ovarian cancer
  • Drug class
  • PARP inhibitor
  • Poly ADP ribose polymerase
  • Mechanism (biology)
  • Medicine
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding